Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Peter MacCallum Cancer Ctr /ID# 252517, Melbourne

Monash Health - Monash Medical Centre /ID# 253841, Clayton

Weill Cornell Medical College /ID# 252516, New York

University of Maryland, Baltimore /ID# 253726, Baltimore

Cancer & Hematology Centers /ID# 252803, Grand Rapids

Wisconsin Medical Center /ID# 252513, Milwaukee

University of Chicago Medical /ID# 252764, Chicago

MD Anderson Cancer Center /ID# 252514, Houston

St. David's South Austin Medical Center /ID# 252790, Austin

City of Hope /ID# 253727, Duarte

Hadassah Medical Center-Hebrew University /ID# 252915, Jerusalem

University of California Davis Health /ID# 252723, Sacramento

The Chaim Sheba Medical Center /ID# 252913, Ramat Gan

Tel Aviv Sourasky Medical Center /ID# 252914, Tel Aviv

Yale University School of Medicine /ID# 252724, New Haven

Northwestern Memorial Hospital /ID# 252800, Chicago

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252515, New York

University of Pennsylvania /ID# 252789, Philadelphia

Fred Hutchinson Cancer Research Center /ID# 253730, Seattle

National Cancer Center Hospital East /ID# 252519, Kashiwa-shi

Yamagata University Hospital /ID# 254105, Yamagata

Seoul National University Hospital /ID# 252916, Seoul

Asan Medical Center /ID# 253955, Seoul

Yonsei University Health System Severance Hospital /ID# 253956, Seoul